MEDXF   $2.24  1.82% Market Closed

MEDEXUS PHARMS INC
Last Events:

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-09 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-06 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-03 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: main and signal line crossing.

2023-08-03 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: signal line crossed the middle level.

2023-08-02 Signal in RSI changed from bearish reversal to bullish recovery. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.

2023-08-02 Trend Power changed from to medium strength.

2023-07-30 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.


Current temperature: 0.82
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 7.00
Mean unverified/preliminary 7.00 / 7.00
Target Price Low / High 7.00 / 7.00
Median / STD DEV 7.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell None
rsi Sell Sell None
macd None None None
stoch None None None
ma20 ActivelyBuy Sell None
ma50 None None None
ma100 None Sell None
Candlestick PatternAug. 11, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CA58410Q2036
ceo Mr. Kenneth d'Entremont
Website https://www.medexus.com
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.